Zurcher Kantonalbank Zurich Cantonalbank cut its holdings in shares of Celgene Co. (NASDAQ:CELG) by 4.8% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 207,933 shares of the biopharmaceutical company’s stock after selling 10,403 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Celgene were worth $19,616,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. Neuberger Berman Group LLC raised its position in shares of Celgene by 2.6% during the 3rd quarter. Neuberger Berman Group LLC now owns 408,133 shares of the biopharmaceutical company’s stock worth $36,524,000 after buying an additional 10,316 shares in the last quarter. Morgan Stanley raised its position in shares of Celgene by 20.4% during the 3rd quarter. Morgan Stanley now owns 3,236,323 shares of the biopharmaceutical company’s stock worth $289,620,000 after buying an additional 549,404 shares in the last quarter. Belpointe Asset Management LLC raised its position in shares of Celgene by 32.0% during the 3rd quarter. Belpointe Asset Management LLC now owns 6,013 shares of the biopharmaceutical company’s stock worth $538,000 after buying an additional 1,459 shares in the last quarter. Diversified Trust Co bought a new stake in shares of Celgene during the 3rd quarter worth about $225,000. Finally, Clearbridge Investments LLC raised its position in shares of Celgene by 9.2% during the 3rd quarter. Clearbridge Investments LLC now owns 7,133,588 shares of the biopharmaceutical company’s stock worth $638,385,000 after buying an additional 598,631 shares in the last quarter. Hedge funds and other institutional investors own 70.78% of the company’s stock.
A number of analysts have commented on CELG shares. Jefferies Financial Group downgraded shares of Celgene from a “buy” rating to a “hold” rating and set a $95.00 price target on the stock. in a research report on Friday, February 1st. BidaskClub upgraded shares of Celgene from a “sell” rating to a “hold” rating in a research report on Friday, May 3rd. William Blair restated a “buy” rating on shares of Celgene in a research report on Thursday, February 28th. Cantor Fitzgerald cut shares of Celgene from an “overweight” rating to a “neutral” rating and set a $94.00 price objective on the stock. in a research note on Friday, April 5th. Finally, Cowen began coverage on shares of Celgene in a research note on Tuesday, February 26th. They issued a “market perform” rating and a $102.00 price objective on the stock. Eighteen equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $95.56.
Shares of Celgene stock traded down $0.39 during trading on Friday, hitting $95.24. The stock had a trading volume of 3,464,800 shares, compared to its average volume of 10,022,681. The company has a market cap of $67.54 billion, a P/E ratio of 12.52, a price-to-earnings-growth ratio of 0.44 and a beta of 1.68. The company has a debt-to-equity ratio of 2.42, a current ratio of 2.78 and a quick ratio of 2.66. Celgene Co. has a 1 year low of $58.59 and a 1 year high of $97.07.
Celgene (NASDAQ:CELG) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping the consensus estimate of $2.45 by $0.10. The business had revenue of $4.03 billion for the quarter, compared to the consensus estimate of $4.01 billion. Celgene had a net margin of 30.10% and a return on equity of 106.69%. The firm’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same period last year, the firm posted $2.05 earnings per share. On average, analysts expect that Celgene Co. will post 9.85 EPS for the current fiscal year.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Story: Percentage Gainers
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.